Discover how AstraZeneca's Imfinzi, approved for resectable NSCLC, offers new hope with a 32% reduced recurrence risk, transforming patient care in Europe.
Explore AstraZeneca's Enhertu approval in the EU for HER2-low breast cancer, backed by significant trial success and a commitment to revolutionizing treatment options.
AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.
Explore Replimune Group, Inc.'s Q4 2024 financial report. Key insights on losses, cash management, and clinical trial outcomes suggest a 'Hold' stock recommendation.
Explore ESSA Pharma Inc.'s financial standing as of Dec 31, 2024. With no revenue and legal challenges, a 'Hold' recommendation is advised for investors.
HUTCHMED (China) Limited's SEC Form 6-K reveals full NMPA approval for ORPATHYS, enhancing market prospects for treating advanced NSCLC. Filed January 14, 2025.
Discover EDAP TMS S.A.'s impressive Q4 2024 preliminary results, featuring record Focal One sales and a 30% growth in U.S. prostate cancer procedures. Learn about future expectations and risks.
Explore EDAP TMS S.A.'s latest financial insights, including board member appointment, Focal One platform expansion, and strategic focus on HIFU technology applications.
CytoMed Therapeutics Limited has signed a Business Research Collaboration with Sunact Cancer Institute to conduct clinical trials for gamma delta T Cells in South Asia, enhancing its market presence.
Explore Citius Oncology's Q4 2024 financial analysis, highlighting a $21.15M net loss, $112 cash, and crucial R&D commitments. Investors advised to hold amidst uncertainties.
Explore AstraZeneca's recent MAA withdrawal for datopotamab deruxtecan, ongoing trials, and strategies in advancing lung cancer therapies.
Explore ESSA Pharma Inc.'s financial performance, stock recommendation, and market challenges. Key insights on liquidity, clinical trial setbacks, and future outlook for investors.